Showing 401 - 420 results of 428 for search '"Hepatitis B"', query time: 0.12s Refine Results
  1. 401

    Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis by Kwabena Obeng Duedu, Yakhya Dieye, Andreas Ateke Njoh, Jerome Nyhalah Dinga, Jones Soladoye Akinbobola, Funmilayo Ibitayo Deborah Afolayan, Tesfaye Kassa, David Dazhia Lazarus, Gezahegne Mamo Kassa, Nefefe Tshifhiwa, Mustapha Oumouna

    Published 2025-01-01
    “…Global vaccination coverage for tuberculosis, diphtheria/tetanus/pertussis, hepatitis B, Haemophilus influenzae type b, measles, polio, meningitis and HPV had a significantly higher coverage than COVID-19. …”
    Get full text
    Article
  2. 402

    Gallstone Ileus following Endoscopic Stone Extraction by Yoshiya Yamauchi, Noritaka Wakui, Yasutsugu Asai, Nobuhiro Dan, Yuki Takeda, Nobuo Ueki, Takahumi Otsuka, Nobuyuki Oba, Shuta Nisinakagawa, Tatsuya Kojima

    Published 2014-01-01
    “…An 85-year-old woman was an outpatient treated at Tokyo Rosai Hospital for cirrhosis caused by hepatitis B. She had previously been diagnosed as having common bile duct stones, for which she underwent endoscopic retrograde cholangiopancreatography (ERCP). …”
    Get full text
    Article
  3. 403

    Time to antiretroviral therapy initiation in HIV-positive patients with opportunistic infections/AIDS-defining illness in Southern Thailand: a prospective cohort study by Chanadda Wuttikul, Nattasiri Thanawuth, Malee Rojpibulsatit, Sutthiporn Pattharachayakul

    Published 2024-04-01
    “…On the other hand, the factors associated with a longer time to ART initiation were tuberculosis co-infection (aHR = 0.52; 95% CI: 0.36-0.75), HIV diagnosis after OIs/ADI (aHR = 0.42; 95% CI: 0.30-0.57), viral hepatitis B/C co-infection (aHR = 0.59; 95% CI: 0.39-0.89), seeking care in general hospital and community hospital (aHR = 0.67; 95% CI: 0.49-0.93, and aHR = 0.62; 95% CI: 0.44-0.86, respectively), having more than one hospital admission in the past six months (aHR = 0.60; 95% CI: 0.44-0.81), and history of missed appointments (aHR = 0.62; 95% CI: 0.42-0.91). …”
    Get full text
    Article
  4. 404

    Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases by Marilena Durazzo, Arianna Ferro, Victor Manuel Navarro-Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee

    Published 2025-01-01
    “…Etiology-specific treatments, such as those for hepatitis B and C viruses, are already in clinical use, and efforts to develop new, targeted therapies for other chronic hepatobiliary diseases are ongoing. …”
    Get full text
    Article
  5. 405
  6. 406

    Aflatoxins in Uganda: An Encyclopedic Review of the Etiology, Epidemiology, Detection, Quantification, Exposure Assessment, Reduction, and Control by Timothy Omara, Winfred Nassazi, Tom Omute, Aburu Awath, Fortunate Laker, Raymond Kalukusu, Bashir Musau, Brenda Victoria Nakabuye, Sarah Kagoya, George Otim, Eddie Adupa

    Published 2020-01-01
    “…More efforts should be geared towards awareness creation and vaccination against hepatitis B and hepatitis A to reduce the risk of development of liver cancer among the populace.…”
    Get full text
    Article
  7. 407

    Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

    Published 2025-02-01
    “…Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. …”
    Get full text
    Article
  8. 408

    Identification of a postoperative survival scoring index for adult liver transplantation by Shuai Wang, Xiaohong Lin, Yefu Li, Zhonghao Xie, Ming Zhang, Yicheng Liang, Chuchen Zhu, Yuqi Dong, Ping Zeng, Xiaoshun He, Weiqiang Ju, Maogen Chen

    Published 2025-12-01
    “…Our index also functioned well in predicting long-term mortality, and it was more effective for patients with hepatitis B cirrhosis or hepatocellular carcinoma (HCC).Conclusions We constructed a simplified and effective postoperative survival scoring index to predict short-term complications and survival in adult LT patients.…”
    Get full text
    Article
  9. 409

    Use of Texture Analysis on Noncontrast MRI in Classification of Early Stage of Liver Fibrosis by Ru Zhao, Xi-Jun Gong, Ya-Qiong Ge, Hong Zhao, Long-Sheng Wang, Hong-Zhen Yu, Bin Liu

    Published 2021-01-01
    “…Patients clinically diagnosed with hepatitis B infection, who underwent liver biopsy and noncontrast MRI scans, were enrolled. …”
    Get full text
    Article
  10. 410
  11. 411

    Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America by Lilian Da Silva Santos, Hans Wolff, François Chappuis, Pedro Albajar-Viñas, Marco Vitoria, Nguyen-Toan Tran, Stéphanie Baggio, Giuseppe Togni, Nicolas Vuilleumier, François Girardin, Francesco Negro, Laurent Gétaz

    Published 2018-01-01
    “…Parasitic infections (schistosomiasis; strongyloidiasis) and cooccurrent viral infections (HIV, hepatitis B (HBV), and hepatitis C (HCV)) are especially of concern for clinical care but have been neglected in empirical research. …”
    Get full text
    Article
  12. 412
  13. 413

    MicroRNA-122 protects against interferon-α-induced hepatic inflammatory response via the Janus kinase–signal transducer and activator of transcription pathway by Fanwei Liu, Bowen Liu, Shanshan Xu, Yinhua Ni, Xiaoli Liu

    Published 2025-01-01
    “…Significant overlap in the epidemiology and coinfection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) has been identified, which accelerates the development of severe liver cirrhosis and hepatocellular carcinoma worldwide. …”
    Get full text
    Article
  14. 414

    Causal associations between osteoporosis and HBV infection across Asian and European populations: evidence from Mendelian randomization and colocalization analysis by Zhengnan Li, Jiarui Cao, Ke Li, Yixin Wu, Zhanpeng Luo, Rui Cao, Zhiheng Cheng, Zhendong Tian, Yiyang Han, Yuping Lai, Bangqi Wang, Shen Chen

    Published 2025-01-01
    “…IntroductionClinical studies have demonstrated a potential association between chronic hepatitis caused by hepatitis B virus (HBV) infection and osteoporosis. …”
    Get full text
    Article
  15. 415

    Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study by Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu

    Published 2024-11-01
    “…Results The study included 70 patients with unresectable HCC, predominantly male and infected with Hepatitis B. The median follow-up duration for the whole cohort was 13.8 months (95% CI 11.08–16.7). …”
    Get full text
    Article
  16. 416

    Cryptococcosis in wait-listed liver transplant candidates: Prevalence, manifestations, and risk factors by Wan-Ting Tsai, Aristine Cheng, Yu-Chung Chuang, Cheng-Maw Ho, Yao-Ming Wu, Ming-Chih Ho, Hsin-Yun Sun, Ray-Hung Hu, Yee-Chun Chen

    Published 2025-02-01
    “…Results: Of the 377 candidates with a median MELD-Na score of 18, 84.4% had hepatitis B virus (HBV) infection. Cryptococcosis was diagnosed in 10 (2.6%) candidates, by CrAg in 6, culture in 2, or both in 2. …”
    Get full text
    Article
  17. 417

    Feasibility and Acceptability of Antenatal Hepatitis C Screening: A Pilot Study by Joseph Valamparampil, Jaswant Sira, Maxine Brown, Saket Singhal, Deirdre Kelly

    Published 2024-01-01
    “…Knowledge about blood-borne viruses was limited; 75% of women had some understanding about antenatal hepatitis B (HBV) and human immunodeficiency virus (HIV) testing. …”
    Get full text
    Article
  18. 418
  19. 419

    Supervised Injecting Room Cohort Study (SIRX): study protocol by Lisa Maher, Thomas Kerr, Matthew Hickman, Alexander Thompson, Peter Higgs, Paul Dietze, Paul A Agius, Nick Scott, Daniel O’Keefe, Mark A Stoové, Jack Stone, Dylan Vella-Horne, Ashleigh C Stewart, Amanda Roxburgh, Sione Crawford, Josephine Norman, Zachary Lloyd, Nico Clark

    Published 2025-02-01
    “…The two cohorts are: (1) participants drawn from the existing Melbourne Injecting Drug User Cohort Study (SuperMIX; established in 2008–ongoing) through which participants consent to annual behavioural surveys (including serological testing for HIV and hepatitis B and C viruses) and linkage to administrative data; and (2) the SIRX-Registration Cohort (SIRX-R; established in 2024) comprising registered MSIR clients who consent to a baseline behavioural survey and administrative data linkage including the frequency of SIF use, and the uptake of on-site services. …”
    Get full text
    Article
  20. 420

    Liver damage in patients living with HIV on antiretroviral treatment with normal baseline liver function and without HBV/HCV infection: an 11-year retrospective cohort study in Gua... by Jun Yu, Hao Liang, Fengxiang Qin, Junjun Jiang, Chunwei Qin, Yunxuan Huang, Bingyu Liang, Yuexiang Xu, Jiegang Huang, Zhiliang Xu, Chuanyi Ning, Yanyan Liao, Ning Zang, Jingzhen Lai, Wudi Wei, Li Ye, Xionglin Qin

    Published 2019-04-01
    “…Objective To characterise the association between duration of exposure to antiretroviral treatment (ART) and liver damage in HIV patients with an initially normal baseline liver function and without hepatitis B virus (HBV)/hepatitis C virus (HCV) infection.Methods A retrospective cohort study was conducted in HIV-infected individuals with normal liver function parameters at ART initiation and without HBV/HCV infection, from 14 April 2004 to 13 April 2015 in Guigang city, Guangxi, China. …”
    Get full text
    Article